Separate the weedkiller from the oral rinse, FDA tells maker of OTC drugs

The FDA has issued a warning letter to a company that makes OTC as well as lawn care products, which the agency says it failed to store separately.

From the FDA’s point of view, OTC drugs and weedkiller just don’t mix. That is the message delivered in a newly posted warning letter to an Iowa company that the FDA says hasn’t seemed to learn from past mistakes.   

The FDA sent a warning letter late last month to the owner of Continental Manufacturing Chemist after an inspection of a plant in Madrid, Iowa, which among other things, makes earwax drops, oral rinse, and fluoride toothpastes as well as lawn care and other products.

During the April 2017 visit, investigators discovered that the facility wasn't physically separating the OTC products like the oral rinse from the weedkiller or adhesive remover and didn’t even have quarantine markings to make sure products didn’t get mixed up.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The plant released at least three batches of oral rinse and two batches of fluoride toothpaste without the products being reviewed by the quality unit and did not “thoroughly investigate” most of the product quality discrepancies or customer complaints that were lodged or half of the 16 manufacturing quality discrepancies noted, the letter notes.

The FDA said that the company’s planned responses were not adequate. It also pointed out that a number of the observations had been noted in previous inspections, even though the plant has a consultant advising it about how to meet FDA standards. The agency said it was time for the company management to figure out the shortcomings and get them fixed.

Some of the issues may be addressed with a new $9.2 million, 80,000-square-foot manufacturing plant that the Ames Tribune reported the company intends to build in Huxley, Iowa, about 12 miles from its current home. The Huxley city council approved a $584,000 financial aid package in August to entice Continental to build the plant there instead of accepting an incentive package that would have had it move to a St. Louis, Missouri, suburb. Additionally, the company is slated to get $829,000 in forgivable, interest-free loans and tax credits from the Iowa Economic Development Agency. The company has promised to add 48 new positions to the 50 it currently has at its current facility.  

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.